Free Trial

Veracyte Q3 2024 Earnings Report

Veracyte logo
$31.27 +0.22 (+0.71%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Veracyte EPS Results

Actual EPS
$0.19
Consensus EPS
$0.03
Beat/Miss
Beat by +$0.16
One Year Ago EPS
-$0.03

Veracyte Revenue Results

Actual Revenue
$115.86 million
Expected Revenue
$109.81 million
Beat/Miss
Beat by +$6.05 million
YoY Revenue Growth
+28.60%

Veracyte Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Veracyte Earnings Headlines

Veracyte (VCYT) Shares Cross Above 200 DMA
Stop working weekends (do this 2-minute trick instead)
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Veracyte initiated with a Buy at Craig-Hallum
Craig-Hallum bullish on Veracyte, initiates with a Buy
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

View Veracyte Profile

More Earnings Resources from MarketBeat